[e-drug] Status of triple combination ARVs under Indian Act.

["Beverley Snell" <bev@burnet.edu.au>]

E-DRUG: Status of triple combination ARVs under Indian Act
------------------------------------------------------

Dear colleagues
Very important triple combination ARV tablets have been produced by several Indian generic companies.
One example is
stavudine / lamivudine / nevirapine
The patents on these 3 individual drugs expire 2007/ 2009/ 2010 respectively.

Please could someone clarify the impact of the new Indian Patent 
legislation  concerning production and export of this and other similar 
products.

Is my understanding correct  - that they can continue producing and exporting products they already produce, so long as they pay an appropriate royalty?

Thank you very much
Beverley
-- 

Beverley Snell
Centre for International Health
Macfarlane Burnet Institute for Medical Research & Public Health
GPO Box 2284, Melbourne 3001 Australia
http://www.burnet.internationalhealth.edu.au

Telephone 613 9282 2115 / 9282 2275
Fax 61 3 9282 2144  or  9282 2100
Time zone: 10 hours ahead of GMT.
email <bev@burnet.edu.au>